What Denovo Sciences does

Denovo Sciences is a private AI-driven drug discovery company headquartered in Yerevan, Armenia, founded in 2019. The company builds a proprietary computational platform for structure-based small-molecule drug design that replaces traditional high-throughput screening and library-based virtual screening with first-principles molecular generation. Its integrated platform comprises five purpose-built AI engines: Proteus for optimal protein conformation selection, Q-Pocket for binding pocket analysis using quantum-annotated hotspot clouds, the Denovo Platform for de novo molecule generation using generative AI and reinforcement learning, HADES (Holistic AI-based Drug-likeness Estimation System) for evaluating 100+ physicochemical, ADMET, and structural features, and Synthony for retrosynthesis planning using a building-block-first paradigm. Validated performance benchmarks include 50,000 compounds per week generation throughput, 89.1% drug-likeness prediction accuracy on external datasets, 74% top-1 retrosynthesis accuracy on USPTO50k, and experimentally confirmed in vitro and in vivo anti-influenza activity.

The company serves pharmaceutical companies, biotechnology firms, and academic research institutions seeking to accelerate early-stage drug discovery, particularly for targets where conventional and AI-based methods have struggled. It monetizes through three channels: software licensing (cloud, API, or on-premise deployment on a subscription basis), discovery services (hit finding, lead finding, lead optimization), and co-discovery/shared development partnerships with shared risk and licensing economics. Strategic partners include Flagship Pioneering, University of Oxford, Weill Cornell Medicine, and CIRI, with three co-founders (CEO Hovakim Zakaryan, CAIO Vardan Harutyunyan, CTO Mher Matevosyan) and an advisory board of senior pharma and AI veterans from GSK, J&J, and Insilico Medicine.

As of the available data, the company has 11-50 employees, has tested 300+ AI-generated molecules across 6 drug discovery programs with a 30% average hit rate, and operates on disclosed funding of approximately $626,236 across four rounds since 2020. No customer logos, ARR, or revenue figures are publicly disclosed.

Name

Denovo Sciences

Legal name

Denovo Sciences

Website

https://denovosciences.ai

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Denovo Sciences is an Armenia-based AI drug discovery company building a proprietary platform of five integrated engines for de novo small-molecule design, serving pharmaceutical and biotechnology partners via software licensing, discovery services, and co-development partnerships.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• AI drug discovery
• Computational drug design
• Small-molecule therapeutics
• Generative molecular design
• Structure-based drug discovery

Headquarters

HQ city

Yerevan

HQ country

Armenia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Software Licensing: Access to proprietary AI-powered drug discovery technologies via cloud-based solutions, API integration, or on-premise deployment. Provides flexible deployment options for partners.
2. Discovery Services: End-to-end drug discovery support including hit finding, lead finding, and lead optimization services leveraging the AI-driven platform.
3. Co-Discovery/Shared Development Partnerships: Joint discovery and advancement of promising candidates from hit to preclinical stages with partners, enabling shared risk and reward in drug development.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels2 records

Core offering

Denovo Sciences builds an AI-powered computational platform for structure-based small-molecule drug discovery. The integrated platform combines proprietary generative AI, retrosynthesis prediction (Synthony), drug-likeness evaluation (HADES), and target/binding-pocket analysis (Proteus, Q-Pocket) to design, evaluate, and prioritize novel drug-like compounds de novo within target binding pockets. The company also delivers discovery services and co-development partnerships to pharmaceutical and biotech clients.

Product overview

Denovo Sciences offers an AI-powered drug discovery platform comprising a core Denovo Platform generative engine plus multiple integrated modules: HADES for drug-likeness evaluation (100+ features), Synthony for retrosynthesis planning, Q-Pocket for binding pocket analysis, and Proteus for target conformation selection. These modules work together in an end-to-end workflow from target selection through synthesizable molecule generation and prioritization.

Differentiator

Problem solved

Functional benefit

Brands

• Denovo Platform: AI-powered generative engine for small-molecule drug discovery, providing integrated molecular design, evaluation, and optimization workflows.
• HADES
• Synthony
• Q-Pocket
• Proteus

Products and services

• Denovo Platform Core AI-powered generative engine platform for de novo small-molecule drug discovery; generates novel, synthesizable, drug-like compounds from first principles within target binding pockets, producing up to 50K compounds per week with 100% chemical validity. Sold to pharmaceutical and biotech partners via cloud, API, or on-premise deployment.
• HADES (Holistic AI-based Drug-likeness Estimation System) Proprietary engine for rapid drug-likeness evaluation that integrates 100+ structural, physicochemical, ADMET, and chemical-alert features into a unified score with detailed rationales; assesses 20 molecules per second at 89.1% accuracy on external datasets. Used to prioritize generated compounds for drug development.
• Synthony AI-driven retrosynthesis platform using a building-block-first paradigm to predict synthon sets from target structures, construct forward synthesis trees from purchasable building blocks, and score routes on feasibility, availability, cost, and commercial viability (74% top-1 accuracy on USPTO50k).
• Q-Pocket Automated toolkit for binding pocket conformation selection using quantum-annotated hotspot clouds; benchmarks conformations against functional criteria and delivers sub-minute extraction and featurization for de novo generation readiness.
• Proteus Proprietary platform that systematically analyzes and benchmarks all available protein conformations in the Protein Data Bank against known active compounds and decoys to recommend optimal target conformations for structure-based drug design.
• Discovery Services End-to-end drug discovery service engagements including hit finding, lead finding, and lead optimization delivered to pharmaceutical and biotech partners using the Denovo AI platform.
• Co-Discovery / Shared Development Partnerships Joint discovery and advancement partnerships where Denovo and a partner share risk and reward in moving candidates from hit stage to preclinical, combining Denovo's AI capabilities with partner resources and domain expertise.
• Software Licensing (Cloud / API / On-Premise) Licensed access to the Denovo Platform, HADES, Synthony, Q-Pocket, and Proteus technologies delivered via cloud-based solutions, API integration into partner workflows, or on-premise deployment for organizations with data sovereignty or integration requirements.

Quantifiable outcome

• 30% average hit rate across drug discovery programs
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• Flagship PioneeringcoreStrategic or Co-development PartnerFlagship Pioneering is a prominent life sciences venture firm and innovation studio. The nature of the partnership with Denovo Sciences suggests strategic collaboration in the drug discovery space, potentially involving funding and strategic guidance for AI-powered pharmaceutical development.
• CIRIcoreStrategic or Co-development PartnerCIRI appears to be a research institution or center involved in infectious disease research. The partnership likely focuses on collaborative antiviral drug discovery projects utilizing Denovo's AI platform.
• ChuvcoreStrategic or Co-development PartnerChuv appears to be a research institution (likely referencing Chuvashia or a specific research center). The partnership enables access to academic research capabilities and validates the scientific rigor of Denovo's platform through institutional collaboration.
• OxfordcoreStrategic or Co-development PartnerUniversity of Oxford is one of the world's leading research universities. The partnership provides academic validation, research collaboration opportunities, and access to cutting-edge scientific expertise in structural biology and drug discovery.
• Weill CornellcoreStrategic or Co-development PartnerWeill Cornell Medicine is a leading medical research institution. The partnership supports translational research initiatives and provides clinical perspective for drug development programs.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Insilico Medicine: Direct competitor in AI-driven small-molecule drug discovery. Both companies combine generative chemistry, target ID, and predictive ADMET into end-to-end pipelines; Insilico's former CAIO (Artur Kadurin) sits on Denovo's advisory board, underscoring direct comparability.
• Schrödinger, Inc. Operates a physics-based computational chemistry platform (including FEP+ and LiveDesign) that overlaps directly with Denovo's structure-based design and molecular modeling capabilities for pharma R&D.
• Recursion Pharmaceuticals: AI-native drug discovery company combining high-throughput biology with machine learning to drive small-molecule pipelines; comparable as an end-to-end generative discovery platform targeting pharma partnerships and internal pipeline development.
• Exscientia: Pioneer in AI-driven small-molecule drug design with an end-to-end platform and pharma co-discovery partnerships; directly comparable to Denovo's generative chemistry plus discovery services model.
• Atomwise: AI small-molecule discovery platform serving pharma partners via software licensing and co-discovery — directly comparable GTM and technology footprint to Denovo's structure-based generative approach.
• XtalPi: Combines AI, physics-based modeling, and robotic synthesis for small-molecule drug discovery; directly comparable on the integration of generative design with retrosynthesis and drug-likeness assessment (HADES/Synthony equivalents).

Emerging players

• Iambic Therapeutics: Earlier-stage AI drug-discovery platform with comparable generative chemistry and physics-based modeling capabilities; overlaps with Denovo's structure-based design and ADMET prediction stack.
• Aria Pharmaceuticals: AI-driven small-molecule discovery using integrated omics and chemistry ML; overlaps with Denovo's pharma partnership and indication-pivot strategy at similar early-stage scale.

Broad incumbents

• Isomorphic Labs: Alphabet-backed AI-drug-discovery venture building an integrated platform from target ID to molecule design; broader in scope and capital but a comparable end-to-end generative drug-discovery vision.
• BenevolentAI: Established AI-drug-discovery company combining knowledge graphs with ML to identify targets and small molecules; comparable in target-to-molecule scope, though typically more target-ID focused than Denovo's de novo design emphasis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/denovo-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Denovo Sciences